5-Azacytidine CAS 320-67-2 Purity: ≥99.0% (HPLC) Factory High Purity

Short Description:

Name: 5-Azacytidine 

CAS: 320-67-2

Appearance: White or Almost White Crystalline Powder

Purity: ≥99.0% (HPLC) 

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Manufacturer with High Purity and Stable Quality
Name: 5-Azacytidine
CAS: 320-67-2
High Quality, Commercial Production
Supply Nucleosides Intermediates

Chemical Properties:

Name 5-Azacytidine
Synonyms Azacitidine; 5-AzaC; Vidaza; Ladakamycin
CAS Number 320-67-2
CAT Number RF-PI194
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C8H12N4O5
Molecular Weight 244.21
Melting Point 226.0-232.0℃ (dec.) (lit.)
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White or Almost White Crystalline Powder 
Purity / Analysis Method ≥99.0% (HPLC)
Loss on Drying ≤1.0%
Residue on Ignition ≤0.50%
Heavy Metals (as Pb) ≤20ppm
Single Impurity ≤0.50%
Total Impurities ≤1.0%
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediates; Organic Synthesis

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 5-Azacytidine (CAS: 320-67-2) with high quality. 5-Azacytidine (CAS: 320-67-2) (brand name: Vidaza) is an anti-cancer chemotherapy medication. The drug is classified as demethylation and antimetabolite agent. Azacytidine acts by inhibiting the growth and proliferation of cancer cells in the body. The drug is indicated for the treatment of specific types of blood cell disorders and bone marrow cancers. Azacytidine is prescribed for treating patients with secondary types of myelodysplastic syndrome, including refractory anemia that presents in the form of ringed sideroblasts (especially if it necessitates transfusion), or it presents itself alongside thrombocytopenia or neutropenia.

  • Write your message here and send it to us